Hepatology may have problems with putative surrogate outcome measures

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Abnormal Liver Tests and Fatty Liver on Ultrasound
Primary prevention of variceal haemorrhage: A pharmacological approach
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Non-invasive diagnosis of non-alcoholic fatty liver disease
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Volume 14, Issue 4, Pages (April 2015)
Living donor liver transplantation: is the hype over?
Volume 42, Issue 4, Pages (April 2005)
Reply to: “DCD consensus and futility in liver transplantation”
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
The place of downstaging for hepatocellular carcinoma
Volume 58, Issue 3, Pages (March 2013)
Short-Bowel Syndrome Clinical Gastroenterology and Hepatology
Autoimmune hepatitis: A life-long disease
Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials  Stephen B Hanauer, Ulf Strömberg 
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 44, Issue 1, Pages (January 2006)
Jennifer M. Croswell, Barnett S. Kramer  Journal of Hepatology 
Volume 62, Issue 3, Pages (March 2015)
Volume 44, Issue 1, Pages (January 2006)
Management of cirrhosis due to chronic hepatitis C
Volume 44, Issue 3, Pages (March 2006)
Andres Cardenas, Pere Ginès  Journal of Hepatology 
Volume 62, Issue 1, Pages (January 2015)
Severe Constipation Clinical Gastroenterology and Hepatology
EASL Clinical Practice Guidelines: Wilson’s disease
Abnormal Liver Tests and Fatty Liver on Ultrasound
Volume 41, Issue 4, Pages (October 2004)
Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola 
Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud 
Volume 50, Issue 4, Pages (April 2009)
Liver stem cells—prospects for clinical use
Volume 67, Issue 5, Pages (November 2017)
Immigration and viral hepatitis
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
HCV targeting of patients with cirrhosis
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Issue Highlights Clinical Gastroenterology and Hepatology
Chronic hepatitis B in children and adolescents
Volume 66, Issue 3, Pages (March 2017)
Volume 62, Issue 3, Pages (March 2015)
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence  Christian Toso, Gilles Mentha, Pietro.
Volume 66, Issue 4, Pages (April 2017)
New trials and results in systemic treatment of HCC
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Volume 50, Issue 1, Pages 4-6 (January 2009)
The relationship between age and fat infiltration in liver and muscle
Josep M. Llovet, Robert Montal, Augusto Villanueva 
Volume 50, Issue 2, Pages iii-iv (April 2019)
Presentation transcript:

Hepatology may have problems with putative surrogate outcome measures Christian Gluud, Jesper Brok, Yan Gong, Ronald L. Koretz  Journal of Hepatology  Volume 46, Issue 4, Pages 734-742 (April 2007) DOI: 10.1016/j.jhep.2007.01.003 Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Basics of validation of a potential surrogate outcome measure (I). In order to function as a potential surrogate, the treatment (TR) must be instituted before the surrogate outcome measure (SO) is evaluated. Further, the evaluation of the surrogate outcome measure must occur before measuring the clinical outcome (CO). Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology 2007 46, 734-742DOI: (10.1016/j.jhep.2007.01.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Basics of validation of a potential surrogate outcome measure (II). In order to function as a potential surrogate, the surrogate outcome measure (SO) must be correlated to the clinical outcome measure (CO). This can be shown in an observational study or in a randomised trial. When the correlation is established it is time to go to the next step in the validation of the potential surrogate for the offered treatment (TR): please see Fig. 3. Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology 2007 46, 734-742DOI: (10.1016/j.jhep.2007.01.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Basics of validation of a potential surrogate outcome measure (III). In order to become a validated surrogate outcome measure for the offered treatment (TR) randomised trials ought to establish that the treatment has significant beneficial effects on the potential surrogate outcome measure (SO) and the clinical outcome measure (CO). The evaluation of the surrogate outcome and the clinical outcome measure is best performed based on data from meta-analyses of several randomised trials on the topic. Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology 2007 46, 734-742DOI: (10.1016/j.jhep.2007.01.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions